Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
To investigate the Safety and Efficacy of Acarbose+Saxagliptin Compared With
Metformin+Saxagliptin in Patients With Type 2 Diabetes,100 patients with T2DM will be
enrolled in this study.They will randomly be assigned to Acarbose+Saxagliptin or
Metformin+Saxagliptin group.HbA1c，fasting and postprandial C-peptide will be observed before
and after the interventions.